Journal Reviews

Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial?

12 October 2022 | | Urologic Oncology | #BladderCancer, #blcsm, cytosine arabinoside, intravesical therapy, mitomycin C, non-muscle-invasive bladder cancer, randomised trial, #uroonc, urinary pH

Mitomycin C (MMC) is often used as an intravesical therapy for low / intermediate risk non-muscle invasive bladder cancer. This randomised controlled trial (RCT) was designed to assess the safety and efficacy of MMC + cytosine arabinoside (Ara-C). Ara-C was...

BJUI International journal cover image.

BCG after TURBT – does timing matter?

2 March 2022 | | Urologic Oncology | #BladderCancer, #blcsm, #uroonc, BCG-unresponsive, bacille Calmette-Guérin, bladder cancer, intravesical therapy, transurethral resection of bladder tumour

Intravesical bacille Calmette–Guerin (BCG) therapy continues to be widely used for patients with intermediate / high-risk non-muscle invasive bladder cancer (NMIBC). In this article, the researchers identified the lack of sufficient evidence with regards to timing of BCG after transurethral...